Brentuximab vedotin

SOURCE: no UK SPC was fetched in this bundle — this draft is distilled from the US ADCETRIS prescribing information (label date 2025-11-11) and must be verified against the UK SPC. INDICATION-SPECIFIC REGIMENS (US Table 1): previously untreated Stage III or IV classical Hodgkin lymphoma — 1.2 mg/kg (max 120 mg) with chemotherapy every 2 weeks until a maximum of 12 doses, disease progression or unacceptable toxicity; classical Hodgkin lymphoma consolidation — 1.8 mg/kg (max 180 mg) every 3 weeks, started within 4 to 6 weeks post auto-HSCT or on recovery from auto-HSCT, up to a maximum of 16 cycles; relapsed classical Hodgkin lymphoma — 1.8 mg/kg (max 180 mg) every 3 weeks until progression or unacceptable toxicity; previously untreated systemic ALCL or other CD30-expressing peripheral T-cell lymphomas — 1.8 mg/kg (max 180 mg) with chemotherapy every 3 weeks for 6 to 8 doses; relapsed systemic ALCL — 1.8 mg/kg (max 180 mg) every 3 weeks until progression or unacceptable toxicity; relapsed primary cutaneous ALCL or CD30-expressing mycosis fungoides — 1.8 mg/kg (max 180 mg) every 3 weeks up to a maximum of 16 cycles; relapsed or refractory LBCL — 1.2 mg/kg (max 120 mg) with lenalidomide and rituximab every 3 weeks until progression or unacceptable toxicity. HEPATIC IMPAIRMENT: previously untreated Stage III or IV classical Hodgkin lymphoma — reduce to 0.9 mg/kg (max 90 mg) every 2 weeks in mild impairment (Child-Pugh A); relapsed or refractory LBCL — reduce to 0.9 mg/kg (max 90 mg) every 3 weeks in mild impairment; all other indications — reduce to 1.2 mg/kg (max 120 mg) every 3 weeks in mild impairment (Child-Pugh A). Avoid use in moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment. PROPHYLAXIS: give G-CSF beginning with Cycle 1 in adults with previously untreated Stage III or IV cHL treated with ADCETRIS plus doxorubicin, vinblastine and dacarbazine (AVD); in paediatric patients with previously untreated high-risk cHL treated with ADCETRIS plus doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVEPC); and in adults with previously untreated PTCL treated with ADCETRIS plus cyclophosphamide, doxorubicin and prednisone (CHP). NOTE: the fetched section 2 was truncated at the source-fetch limit after section 2.4, so any further dosing content (including remaining prophylaxis and administration detail) was not retrieved.

US labelling only (no UK SPC in this bundle) — for paediatric patients 2 years and older with previously untreated HIGH RISK classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide. Safety and effectiveness have NOT been established for any other paediatric indication, nor in patients younger than 2 years. Clinician to verify against the UK SPC.